This Vaccine Helps Protect Your Brain and prevent dementia : Learn more
Updated: Sep 9
For years, scientists have suspected that preventing infections might also help protect the brain. Now, growing evidence suggests that the shingles vaccine may lower the risk of developing dementia and the data behind this idea is stronger than you might think.
Why This Evidence Is Different (and More Convincing)
Most studies linking vaccines to lower dementia risk have been observational, which means healthier people might simply be more likely to get vaccinated, a problem called “healthy vaccinee bias.”
What makes the shingles–dementia connection especially compelling is that multiple recent studies used “natural experiments.” These studies take advantage of real-world vaccination policies based on date-of-birth cutoffs, creating groups of people who are nearly identical, except for whether they were eligible for the vaccine.
This design closely mimics randomization and greatly reduces bias.
What the Natural Experiments Found
Three large, independent studies from different countries all reached similar conclusions:
Wales: People born just after September 2, 1933 (eligible for shingles vaccination) had a 20% lower risk of dementia over 7 years compared with those born just before the cutoff.
Australia: Vaccine eligibility was associated with a 2 percentage point absolute reduction in dementia risk over ~7 years.
Canada (Ontario): A 2.0 percentage point absolute risk reduction in dementia diagnoses over 5.5 years, confirmed across multiple analytical methods.
In one study, vaccination rates differed dramatically between groups (about 47% vs 0.01%), yet the groups were otherwise nearly identical in health and behavior, making confounding very unlikely.
What Do Larger Meta-Analyses Show?
When researchers pooled data from millions of participants, the results were consistent:
A 24–32% lower risk of dementia among people who received the shingles vaccine
One analysis of over 14 million individuals found a 29% risk reduction
Another showed a 24% reduction for all-cause dementia
While individual studies vary, the direction of benefit is remarkably consistent.
Does the Type of Shingles Vaccine Matter?
Both shingles vaccines appear protective:
Live-attenuated vaccine (Zostavax)
Recombinant vaccine (Shingrix)
For Shingrix, protection seems dose-dependent:
Two doses → ~32% lower dementia risk
One dose → smaller benefit
Some evidence suggests the protective effect may wane over time, similar to how protection against shingles itself decreases, hinting that preventing viral reactivation may be key.
How Could a Shingles Vaccine Protect the Brain?
Researchers are still piecing this together, but several plausible mechanisms exist:
1. Preventing viral damage to the brain
Reactivation of the shingles virus (varicella-zoster virus) has been linked to:
Blood vessel inflammation in the brain
Small strokes and microvascular disease
Amyloid and tau accumulation
Chronic neuroinflammation
Preventing reactivation may interrupt these processes before long-term damage occurs.
2. Reducing repeated viral hits
Recurrent shingles episodes are associated with higher dementia risk, while antiviral treatment during shingles infections appears protective, supporting a causal role for viral activity.
3. Immune system “training”
Some vaccines, especially live vaccines, may recalibrate the immune system to respond more efficiently, reducing harmful inflammation over time. Whether this contributes meaningfully beyond virus suppression remains an open question.
What Are the Limitations?
There are no randomized controlled trials yet, which researchers openly acknowledge are needed.
Observational studies show high statistical heterogeneity, likely due to differences in populations, dementia definitions, and follow-up length, not because results conflict.
The Bottom Line
While the shingles vaccine is currently recommended to prevent shingles and its complications, evidence increasingly suggests it may offer an unexpected bonus: reduced dementia risk.
These findings do not mean the vaccine should be prescribed solely for dementia prevention, but they add to a growing body of research showing how infection prevention may be brain protection.
As researchers continue to explore this link, the shingles vaccine stands out as one of the most promising and practical interventions we currently have that may influence long-term brain health.
Preventiononly takeaway:
Preventing disease early often has benefits far beyond what we initially expect. Brain health may start with immune health. At Preventiononly we believe routine vaccinations prevent disease, saves lives and improves quality of life. To learn more about our methods, go to www.preventiononly.com
FAQs
Can the shingles vaccine really lower my risk of dementia?
Growing research suggests it might. Large studies following millions of people found that those who received the shingles vaccine were less likely to develop dementia over several years compared with those who did not.
How strong is the evidence?
The evidence is stronger than for many lifestyle studies. Several studies used natural experiments, comparing people born just days apart, making them nearly identical except for vaccine eligibility. These studies showed meaningful reductions in dementia risk, making a causal link more likely.
How much could the risk be reduced?
Depending on the study, people who received the shingles vaccine had about a 20–30% lower risk of dementia over 5–7 years. This does not guarantee prevention, but it may lower risk.
How could a shingles vaccine affect the brain?
Shingles virus reactivation can cause inflammation, blood vessel injury, and possibly long-term brain damage. Preventing reactivation may:
Reduce brain inflammation
Lower stroke-like injury in the brain
Reduce processes linked to Alzheimer’s disease
Does the protection last forever?
Protection may decrease over time, similar to how shingles protection itself can wane. Ongoing research is evaluating how long the brain benefits last.
Should I get the shingles vaccine to prevent dementia?
The vaccine is not officially recommended solely for dementia prevention. However, if you are eligible, vaccination may offer additional brain-health benefits beyond preventing shingles.
Who should get the shingles vaccine?
In the U.S., Shingrix is recommended for adults aged 50 and older, and for some adults 19+ with weakened immune systems. Always discuss timing and eligibility with your healthcare provider.
Is the vaccine safe?
Yes. Shingrix has been extensively studied and is considered safe and effective. Temporary side effects like arm soreness or fatigue are common and usually short-lived.
What’s the takeaway?
Preventing infections may help protect the brain. While more research is ongoing, the shingles vaccine appears to be a simple, low-risk step that may support long-term cognitive health.
References
1. Herpes Zoster Vaccination and Dementia Occurrence. Pomirchy M, Bommer C, Pradella F, et al. JAMA. 2025;333(23):2083-2092. doi:10.1001/jama.2025.5013.
2. Varicella-Zoster Virus Reactivation and the Risk of Dementia. Polisky V, Littmann M, Triastcyn A, et al. Nature Medicine. 2025;:10.1038/s41591-025-03972-5. doi:10.1038/s41591-025-03972-5.
3. Recombinant Zoster Vaccine and the Risk of Dementia. Tang E, Ray I, Arnold BF, Acharya NR. Vaccine. 2025;46:126673. doi:10.1016/j.vaccine.2024.126673.
4. Impact of Herpes Zoster Vaccination on Incident Dementia: A Retrospective Study in Two Patient Cohorts. Scherrer JF, Salas J, Wiemken TL, et al. PloS One. 2021;16(11):e0257405. doi:10.1371/journal.pone.0257405.
5. Herpes Zoster Vaccination and Incident Dementia in Canada: An Analysis of Natural Experiments. Pomirchy M, Chung S, Bommer C, Strobel S, Geldsetzer P. The Lancet. Neurology. 2026;25(2):170-180. doi:10.1016/S1474-4422(25)00455-7.
6. A Natural Experiment on the Effect of Herpes Zoster Vaccination on Dementia. Eyting M, Xie M, Michalik F, et al. Nature. 2025;641(8062):438-446. doi:10.1038/s41586-025-08800-x.
7. Effects of Herpes Zoster Infection, Antivirals and Vaccination on Risk of Developing Dementia: A Systematic Review and Meta-Analysis. Marra F, Gomes K, Liu E, et al. Human Vaccines & Immunotherapeutics. 2025;21(1):2546741. doi:10.1080/21645515.2025.2546741.
Comments